These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20040317)

  • 1. LSDs and the immune system.
    Beck M; Vanier M
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S85. PubMed ID: 20040317
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives from B cell immunology: fact and fancy.
    Hunt SV
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.
    Broomfield A; Jones SA; Hughes SM; Bigger BW
    J Inherit Metab Dis; 2016 Jul; 39(4):499-512. PubMed ID: 26883220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximizing the therapeutic potential of enzyme replacement therapy for lysosomal storage diseases.
    Gieselmann V
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):707-8. PubMed ID: 19954707
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
    Kishnani PS; Dickson PI; Muldowney L; Lee JJ; Rosenberg A; Abichandani R; Bluestone JA; Burton BK; Dewey M; Freitas A; Gavin D; Griebel D; Hogan M; Holland S; Tanpaiboon P; Turka LA; Utz JJ; Wang YM; Whitley CB; Kazi ZB; Pariser AR
    Mol Genet Metab; 2016 Feb; 117(2):66-83. PubMed ID: 26597321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Immune Tolerance Induction in Enzyme Replacement Therapy.
    İnci A; Ezgü FS; Tümer L
    Paediatr Drugs; 2024 May; 26(3):287-308. PubMed ID: 38664313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.
    Wang J; Lozier J; Johnson G; Kirshner S; Verthelyi D; Pariser A; Shores E; Rosenberg A
    Nat Biotechnol; 2008 Aug; 26(8):901-8. PubMed ID: 18688246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment for Lsds: real options for several diseases. Forward.
    Cohen IJ; Baris HN; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():71. PubMed ID: 25345087
    [No Abstract]   [Full Text] [Related]  

  • 13. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune system irregularities in lysosomal storage disorders.
    Castaneda JA; Lim MJ; Cooper JD; Pearce DA
    Acta Neuropathol; 2008 Feb; 115(2):159-74. PubMed ID: 17924126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic reactions to enzyme replacement therapy in children with lysosomal storage diseases and their management.
    Arik E; Keskin Ö; Albayrak S; Keskin M; Cesur M; Karaoglan M; Inal G; Yildirim A; Kucukosmanoglu E
    J Pediatr Endocrinol Metab; 2024 Oct; 37(10):866-874. PubMed ID: 39243118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.
    Haneef SA; Doss CG
    Adv Protein Chem Struct Biol; 2016; 102():225-65. PubMed ID: 26827607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
    Brooks DA; Kakavanos R; Hopwood JJ
    Trends Mol Med; 2003 Oct; 9(10):450-3. PubMed ID: 14557058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.